Physician profile
Umer Syed
NPI 1063806206
$1,758.75
in general payments reported to CMS, 2019-2025
14 companies · $334 in 2025
The $334 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.94 · 2020: $25.95 · 2021: $120 · 2022: $226 · 2023: $577 · 2024: $428 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,338.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $377.75 | 2023-2025 | Lifevest |
| Edwards Lifesciences Corporation | $335.81 | 2020-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $191.77 | 2022-2024 | Repatha |
| Depuy Synthes Sales INC. | $133.28 | 2024 | Na |
| Astrazeneca Pharmaceuticals LP | $128.60 | 2021-2022 | |
| Pfizer INC. | $119.19 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $109.66 | 2023 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $103.94 | 2023-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $70.43 | 2023-2024 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $62.34 | 2023 | |
| Alexion Pharmaceuticals, INC. | $47.94 | 2019 | |
| Novo Nordisk INC | $35.15 | 2023-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.30 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $14.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umer Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.